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Abstract
Objective
To analyze the association between circulating osteoprotegerin (OPG) and Dickkopf-related
protein 1 (DKK-1) and radiological progression in patients with tightly controlled rheumatoid
arthritis (RA).
Methods
Serum levels of OPG and DKK-1 were measured in 97 RA patients who were treated
according to a treat-to-target strategy (T2T) aimed at remission (DAS28<2.6). Radiologic
joint damage progression was assessed by changes in the total Sharp-van der Heijde score
(SHS) on serial radiographs of the hands and feet. The independent association between
these biomarker levels and the structural damage endpoint was examined using regression
analysis
Results
The mean age of the 97 RA patients (68 women) at the time of the study was 54 ± 14 years,
and the median disease duration was 1.6 ± 1.5 years. Most patients were seropositive for
either RF or ACPA, and the large majority (76%) were in remission or had low disease activity.
After a median follow-up time of 3.3 ± 1.5 years (range, 1–7.5 yrs.), the mean total SHS
annual progression was 0.88 ± 2.20 units. Fifty-two percent of the patients had no progres-
sion (defined as a total SHS of zero). The mean serum OPG level did not change signifi-
cantly over the study period (from 3.9 ± 1.8 to 4.07 ± 2.23 pmol/L), whereas the mean serum
DKK-1 level decreased, although not significantly (from 29.9 ± 10.9 to 23.6 ± 18.8 pmol/L).
In the multivariate analysis, the predictive factors increasing the likelihood of total SHS
progression were age (OR per year = 1.10; p = 0.003) and a high mean C-reactive protein
level over the study period (OR = 1.29; p = 0.005). Circulating OPG showed a protective
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effect reducing the likelihood of joint space narrowing by 60% (95% CI: 0.38–0.94) and the
total SHS progression by 48% (95% CI: 0.28–0.83). The DKK-1 levels were not associated
with radiological progression.
Conclusion
In patients with tightly controlled RA, serum OPG was inversely associated with progression
of joint destruction. This biomarker may be useful in combination with other risk factors to
improve prediction in patients in clinical remission or low disease activity state.
Introduction
In rheumatoid arthritis (RA), remission or low disease activity can be achieved with tight con-
trol of inflammation and early use of disease-modifying antirrheumatic agents (DMARD).
The importance of the treat-to-target strategy (T2T) has recently been highlighted by EULAR
recommendations [1,2]. However, the definitions of remission according to clinical criteria,
including disease activity score (DAS), simplified disease activity index (SDAI), and ACR/
EULAR Boolean criteria do not always correspond with the complete absence of inflammation
as measured by sensitive imaging techniques, such as magnetic resonance imaging (MRI) or
ultrasonography (US) [3–6]. Several studies have demonstrated the presence of subclinical
inflammation in a significant number of patients who were considered to be in clinical remis-
sion or at a low state of disease activity [3,6–8]. This persistent subclinical joint activity ulti-
mately lead to radiographic joint damage progression [3,6–8].
Several predictors of clinical outcome and radiographic progression have been proposed in
RA, including traditional inflammatory markers (ESR and C-reactive protein), patient´s char-
acteristics, and genetic, serologic and imaging biomarkers [9–12]. Among serological bio-
markers, recent works have suggested that some bone remodeling markers may be
independent predictors of joint damage in RA [9,13–15]. If the level of a bone remodeling bio-
marker or, particularly the short-term change in the level, may predict radiographic progres-
sion, these markers may constitute disease activity indicators and may also be useful for
clinicial managing of individual patients.
The characteristic trait of RA is a persistent inflammation of the synovial membrane and
the formation of an invasive synovial tissue, called the pannus, that invades and destroys the
adjacent cartilage and subchondral bone. The Receptor Activator of Nuclear Factor Kappa B
Ligand (RANKL), osteoprotegerin (OPG) and Dickkopf-1 (DKK-1) have been demonstrated
to be key molecules involved in bone erosion and bone remodeling [16,17]. The aim of the
present study was to test whether these three bone remodeling biomarkers may serve as pre-
dictors of radiographic progression in patients with tightly controlled RA.
Methods
Study population
An observational longitudinal prospective study was carried out. A total of 97 patients with RA
meeting the 2010 classification criteria for RA [18] were included. All patients were treated in
the Early Arthritis Clinic of Bellvitge Hospital by the same rheumatologist (JN). They were
treated according to a treat-to-target strategy (T2T) aimed at remission (DAS28 < 2.6).
Patients were initially managed with a single synthetic DMARD, mainly methotrexate (MTX)
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or leflunomide (LEF), followed by a synthetic DMARD combination (usually MTX and LEF),
and an exchange of LEF with biologic agents in case of failure.
The study was approved by the Clinical Research Ethics Committee of Bellvitge University
Hospital-IDIBELL; Ref:PR/16511). All patients provided a written informed consent before
participating in the study. The patient´s clinical records and information were anonymized
and de-identified prior to analysis. This study was conducted in accordance with the principles
of the Declaration of Helsinki and the International Conference for Harmonization.
Clinical and laboratory profiles
Radiographs of hands, wrists, and feet were obtained at inclusion of the study and after a mini-
mum follow-up of 1 year (median ± standard deviation: 3.3 ± 1.5 years; range, 1–7.5 yrs). In this
study, time zero (T0) refers to the baseline blood and radiologic examinations, and time one
(T1) to the date of the second radiograph and blood sample. Radiographs were digitalized and
scored for erosions (ERO) and joint space narrowing (JSN) using the Sharp-van der Heijde
score (SHS). The images were independently reviewed by three of the authors (JI, JAN and
JHG) who were blinded to the clinical information and the date of Rx acquisition. Discrepancies
in findings were resolved in a subsequent joint review session and consensus was reached.
The serum OPG, DKK-1 and soluble RANKL levels were measured by commercial ELISA
kits (Biomedica1 Immunoassays, Vienna, Austria) at T0 and T1. Consistent with the kit man-
ufacturer’s instructions [19], samples were immediately centrifuged and stored at -20˚C until
they were assayed. Our initial intention was to evaluate the ratio RANKL / OPG, but the
RANKL values were below the detection limit in 82 (85%) patients. Therefore, in our study, we
ultimately only tested OPG and DKK-1. According to the manufacturers, normal values are
below 2.7 pmol/l for OPG and 34 pmol/l for DKK-1.
The primary outcome measure of the study was the presence of radiographic progression,
which was defined as any increase in the total SHS between baseline (T0) and the second radio-
graph (T1). No progression was defined as a score of zero. The minimal clinically important
difference was defined as an increase of at least 5 points in total SHS.Outpatient charts were com-
prehensively reviewed following a specifically designed protocol. Baseline data collected at T0
included the following: age, gender, body mass index (BMI), disease duration (calculated from
data of the first symptom), presence of extra-articular manifestations, details of past and present
anti-rheumatic therapies (NSAID, steroids, DMARD and the number of biological agents previ-
ously used) and osteoporosis treatments, erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP), and baseline serological status for rheumatoid factor (RF) and anti-citrullinated peptide
antibodies (ACPA). ACPA antibodies were measured using a commercially available second-gen-
eration ELISA kit (EIATM ACPA Assay on the ImmunoCAP250 instrument, Phadia, Germany).
In addition, there was an assessment of disease activity at T0 that included the patient´s
visual analog scale for pain, the swollen and tender joint count in 28 joints, the DAS28-ESR
score, and the health assessment questionnaire (HAQ). As a reflection of articular disease
activity between T0 and T1, we also calculated the mean DAS28-ESR and the mean CRP of all
of the values recorded in the monitoring visits conducted during this period of time.
Statistical analysis
The sample was described by using summary statistics, i.e., the mean, median, standard devia-
tion, and interquartile range for quantitative variables and distribution percentages for qualita-
tive variables.
Crude associations between the presence of radiographic progression expressed in a dichot-
omous variable (progression / no progression) and clinical and laboratory variables were
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investigated by bivariate logistic regression models, expressing the results as an odds ratios
(OR) and significance value.
A multivariate logistic regression analysis was performed to assess the predictive role of the
OPG and DKK-1 levels on radiological progression, controlling for potential confounders
such as age, sex, disease activity, mean corticosteroid dose, and DMARD treatment duration.
The construction of the regression models was perfomed by backward stepwise using both sta-
tistical and clinical judgment. The interaction effect of gender was tested by stratified analysis.
Results
The main demographic and clinical characteristics of the RA study cohort are summarized in
Table 1.
The mean age of the 97 RA patients (68 women) at the time of the study was 54 ± 14 years,
and the median disease duration was 1.6 ± 1.5 years. Most patients were seropositive for either
RF or ACPA, and the large majority (76%) were in remission or had low disease activity.
The median follow-up time between T0 and T1 was 3.3 ± 1.5 years (range, 1–7.5 yrs.). Of
the 97 patients, 62 (64%) received synthetic DMARD monotherapy during the follow-up
period, 15 (15%) received synthetic DMARD combinations, and 20 (21%) ultimately required
biological therapy (12% were taking a TNF inhibitor, 5% rituximab and 4% tocilizumab).
Additionally, 69 (72%) patients also received a concomitant low dose oral glucocorticoid treat-
ment, and 36 (37%) were received antiresorptive or bone-forming therapy (34 with bisphos-
phonates, 1 with denosumab and 1 with teriparatide).
The mean DAS28-ESR value during the follow-up period was 2.6 ± 0.9, and the mean CRP
value was 2.48 ± 0.87 (reference value < 5 mg/L). The mean serum OPG level did not change
significantly over the study period (from 3.9 ± 1.8 to 4.07 ± 2.23 pmol/L), whereas the mean
serum DKK-1 level tended to decrease (from 29.9 ± 10.9 to 23.6 ± 18.8 pmol/L; p = NS. There
were not differences in DKK1 serum levels between patients treated with TNF inhibitors and
patients not treated with biological agents or treated with rituximab or tocilizumab.
The mean total SHS annual progression over the study period (see Table 1) was 0.88 ± 2.20
units (below the minimal clinically important difference). Fifty two percent (50) of the patients
had no progression.
Table 2 shows the results of a bivariate analysis of factors associated with radiographic pro-
gression. The annual ERO score progression was associated with a longer follow-up time
T0-T1, longer duration of synthetic DMARD therapy, and with greater changes in the mean
DAS28-ESR and mean CRP between T0 and T1. The age, BMI, and high CRP levels over the
study period were all associated with the increased probability of JSN progression (6%, 12% and
8%, respectively). Finally, age, BMI, and the higher values of the mean DAS28-ESR and mean
CRP levels over the follow-up period were associated with total SHS progression. Of note, in
this analysis, neither the OPG nor DKK-1 serum levels achieved statistical significance.
On multivariate, no significant differences in the role of the different independent variables
on the basis of sex were observed. In the multivariate analysis (Table 3), ERO score progression
was associated with a longer follow up time T0-T1 and high mean CRP levels over the study
period. JSN and total SHS progression increased with age and also with the higher values of
the mean CRP between T0 and T1. Circulating OPG showed a protective effect reducing the
likelihood of JSN by 60% (OR: 0.60, 95% CI: 0.38–0.94) and the total SHS progression by 48%
(OR: 0.48, 95% CI: 0.28–0.83). The DKK-1 levels were apparently not associated with radiolog-
ical progression.
Neither anti-TNFα therapy or the antiresorptive or bone-forming therapy influenced in the
OPG/DKK1 levels nor in the radiographic progression.
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Discussion
One of the hallmarks of RA is progressive bone erosion. In this entity, erosion of periarticular
cortical bone results from osteoclastic bone resorption at the site of synovitis, where RANKL
expression is found [16]. RANKL is a membrane protein that is secreted by osteoblasts and
Table 1. Main demographic and clinical characteristics of the RA study cohort.
Number of patients 97
Women/men 68 (70%) / 29 (30%)
Age, years 53 ±14
BMI, kg/m2 25.9 ± 4.9
Disease duration (median), years 1.6 ± 1.5
Positive RF 59 (61%)
Positive ACPA 60 (62%)
Systemic extraarticular manifestations* 16 (16%)
DAS28-ESR at T0Baseline disease activity at T0 3.4 ± 1.8
• Remission or low activity disease 71 (76%)
• Moderate 21 (23%)
• High 1 (1%)
HAQ (0–3) 1.38 ± 0.88
ESR (mm/h) at T0 16.7 ± 13.4
CRP (mg/L) at T0 9.6 ± 16.2
OPG (pmol/L) at T0 3.9 ± 1.8
DKK-1 (pmol/L) at T0 29.9 ± 10.9
Follow-up time between T0 and T1, (median) years 3.3 ± 1.5 (range: 1–7.5)
Treatment during follow-up period
• Synthetic DMARD monotherapy 62 (64%)
• Synthetic DMARD combinations 15 (15%)
• Biological therapy + synthetic DMARD 20 (21%)
• Concomitant therapy
 Low-dose oral glucocorticoid treatment 69 (72%)
 Accumulated dose of prednisone (g) 4.28 ± 2.86
Osteoporosis treatment
• None 26 (28%)
• Calcium and Vitamin D 70 (72%)
• Antiresorptive or bone forming therapy 36 (37%)
Mean DAS28-ESR between T0 and T1 2.6 ± 0.95
Mean CRP between T0 and T1 2.48 ± 0.87
Radiological progression (annual difference)
• Erosions 0.19 ± 0.62
• Joint space narrowing 0.68 ± 1.70
• Total Sharp–van der Heijde score 0.88 ± 2.20
Results are presented as mean ± standard deviation (median for disease duration and follow-up time) or
number of cases with percentages.
*Including rheumatoid nodules, pulmonary manifestations, vasculitis, ocular manifestations, and secondary
Sjo¨gren’s syndrome.
Abbreviations: ACPA = anti-citrullinated peptide antibodies; BMI = body mass index; CRP = C-reactive
protein; DAS = disease activity score; DKK-1 = Dickkopf-related protein 1; DMARD = disease modifying anti-
rheumatic drug; ESR = erythrocyte sedimentation rate; HAQ = Health Assessment Questionnaire;
OPG = osteoprotegerin.
doi:10.1371/journal.pone.0166691.t001
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osteocytes under the influence of proinflammatory cytokines, such as tumor necrosis factor-α
(TNF-α), interleukin (IL)-1 and IL-6 [17]. The binding of RANKL to the RANK (Receptor
Activator of Nuclear factor Kappa B) receptors on pre-osteoclasts and mature osteoclasts and
stimulates their activation and differentiation, finally leading to enhanced bone resorption
[13,16]. This bone resorption is inhibited by OPG, which prevents RANKL-RANK interac-
tions [13,16]. Thus, the balance between RANKL and OPG regulates the degree of prolifera-
tion and activity of the osteoclasts, playing a pivotal role in bone erosion.
Crotti et al. showed that synovial RANKL expression is increased in RA patients with active
disease compared with patients with quiescent disease [20]. The increased levels of RANKL in
Table 2. Factors associated with radiographic progression by the Sharp-van der Heijde score (total and by subscales): results of the bivariate
analysis.
Variable Erosion OR (p-value) Joint space narrowing OR (p-value) Total score OR (p-value)
Female sex 0.60 (0.286) 0.73 (0.502) 0.77 (0.569)
Age, per year 1.02 (0.165) 1.06 (0.002) 1.05 (0.003)
BMI, per unit 1.01 (0.881) 1.12 (0.026) 1.11 (0.039)
Disease duration, per year 0.99 (0.960) 0.94 (0.656) 0.99 (0.926)
Follow-up time T0-T1, per year 1.61 (0.005) 0.97 (0.832) 1.05 (0.712)
Positive RF 1.29 (0.596) 1.63 (0.279) 1.53 (0.330)
Positive ACPA 1.00 (0.992) 0.53 (0.148) 0.63 (0.289)
Mean DAS28-ESR between T0 and T1, per unit 1.99 (0.008) 1.41 (0.124) 1.88 (0.009)
Mean CRP between T0 and T1, per unit 1.16 (0.001) 1.08 (0.024) 1.20 (0.002)
OPG1, per pmol /L 0.94 (0.660) 1.04 (0.768) 1.02 (0.866)
DKK-1, per pmol /L 1.02 (0.352) 1.00 (0.959) 1.01 (0.548)
Accumulated glucocorticoid dose, per mg 1.00 (0.180) 1.00 (0.442) 1.00 (0.165)
Duration of synthetic DMARD therapy, per month 1.04 (0.007) 1.00 (0.983) 1.00 (0.724)
Anti-TNFα treatment 0.60 (0.209) 0.88 (0.570) 0.84 (0.417)
Antiresorptive or bone forming therapy 0.65 (0.256) 0.96 (0.737) 0.94 (0.636)
Abbreviations: ACPA = anti-citrullinated peptide antibodies; BMI = body mass index; CRP = C-reactive protein; DAS = disease activity score; DKK-
1 = Dickkopf-related protein 1; DMARD = disease modifying anti-rheumatic drug; ESR = erythrocyte sedimentation rate; OPG = osteoprotegerin; OR = odds
ratio; RF = rheumatoid factor; T0 = baseline visit; T1 = date of the second radiograph.
doi:10.1371/journal.pone.0166691.t002
Table 3. Factors associated with radiographic progression by the Sharp-van der Heijde score (total and by subscales): results of the multivariate
regression models by backward stepwise selection.
Erosion OR (p-value) Joint space narrowing OR (p-value) Total score OR (p-value)
Female sex NS NS NS
Age, per year NS 1.10 (0.004) 1.10 (0.003)
Mean CRP between T0 and T1, per unit 1.18 (0.001) 1.08 (0.047) 1.29 (0.005)
Follow-up time T0-T1, per year 1.61 (0.025) NS NS
Mean DAS28-ESR between T0 and T1, per unit NS NS NS
OPG1, per pmol /L NS 0.60 (0.026) 0.48 (0.008)
DKK-1, per pmol /L NS NS NS
Accumulated glucocorticoid dose, per mg NS NS NS
Duration of synthetic DMARD therapy, per month NS NS NS
Anti-TNFα treatment NS NS NS
Abbreviations: CRP = C-reactive protein; DAS = disease activity score; DKK-1 = Dickkopf-related protein 1; DMARD = disease modifying anti-rheumatic
drug; ESR = erythrocyte sedimentation rate; OPG = osteoprotegerin; OR = odds ratio; T0 = baseline visit; T1 = date of the second radiograph.
Erosion: Pseudo R2 = 0.25; Space narrowing: Pseudo R2 = 0.17; Total score: Pseudo R2 = 0.33
doi:10.1371/journal.pone.0166691.t003
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inflamed joints lead to a high RANKL/OPG ratio, reflecting bone destruction, which is predic-
tive of increased radiological progression. In this sense, Van Tuyl et al. found that a high base-
line RANKL/OPG ratio in patients with early, active untreated RA was a strong independent
predictor of rapid and persistent damage progression over the 11-year follow-up in the
COBRA study [21]. The results from the logistic regression analysis performed at 5 years of
this study showed that a high RANKL level gave an OR of 4.4 (1.5–13.0) for progression and
high OPG levels, an OR of 0.29 (0.10–0.85) [22]. These data are in agreement with our results,
as we also found that serum OPG may have a protective effect on radiographic disease progres-
sion, reducing the likelihood of joint space narrowing by 60% and the total SHS progression
by 48%. Previous studies have demonstrated that OPG is decreased in the synovium and
serum of active RA patients [23]. By contrast, increased serum OPG was found after TNF-α
inhibitor treatment in RA patients [24], in the same way that OPG expression is increased in
the synovium of anti-TNF treated patients [25]. Furthermore, it was recently shown that
genetic variants in OPG are associated with progression of joint destruction in RA [26].
In our study, our initial intention was to evaluate the RANKL / OPG ratio, but the RANKL
values were below the detection limit in 85% of the patients. This may be explained by the fact
that it was a cohort of RA patients treated according to treat-to-target strategy who mostly
(76%) were in remission or had low disease activity at the time of the study. Several studies
[27–29] have demonstrated that TNF-α inhibitors and some synthetic DMARDs (such as
MTX and sulfasalazine) inhibit the expression of RANKL in RA synoviocytes while augment-
ing the secretion of OPG in synoviocyte supernatants, and they all inhibited osteoclast forma-
tion in vitro. In addition, we cannot forget that the accurate measurement of circulating
RANKL is very difficult because of uncertain factors about which forms are the most biologi-
cally relevant and the limited sensitivity of available assays [9,13,14]. In this sense, Chan et al.
showed significant (> 50%) alterations in serum concentration of RANKL after storage for 6
months at both -20˚C and -70˚C [30].
In addition to the OPG/RANK/RANKL pathway, several lines of evidence show that the
Wnt signaling pathway also significantly participates in RA pathogenesis. DKK-1 is an endoge-
nous, secreted inhibitory factor in canonical Wnt signaling by binding the Wnt coreceptor
LRP5/6 [31]. DKK-1 is thought to be the main determinant of the uncoupling of bone remod-
elling in RA: bone resorption and bone formation are uncoupled in favor of resorption. In
addition, studies have demonstrated that activation of the Wnt signaling pathway in mature
osteoblasts upregulates OPG, which blocks RANKL-induced osteoclastogenesis and results in
the inhibition of bone resorption [32,33]. When DKK-1 is increased by TNF-α, it exerts its
negative regulation on the WnT pathway, decreasing the expression of OPG, enhancing the
RANKL/RANK interaction, blocking osteoblast differentiation and inducing the expression of
sclerostin, leading to the death of osteocytes [34]. DKK-1 also plays a key role in the promotion
of synovial angiogenesis [35].
The serum levels of DKK-1 are significantly higher in patients with active RA than in
healthy controls [15], and the change in the DDK-1 levels may serve as a biomarker of disease
activity and radiographic progression [9,15,36]. Garnero et al. found that higher levels of
DKK-1 are associated with an increased risk of articular erosions independent of age, baseline
radiographic features, CRP or disease activity [36]. However, in our study, circulating DKK-1
was not an independent predictor of radiographic progression. This discrepancy can also be
explained by the characteristics of our RA cohort, consisting of mostly patients with low dis-
ease activity or who were in remission. In this sense, it has been demonstrated that circulating
DDK-1 decreases after treatment with TNF-α inhibitors or the IL-1 receptor antagonist ana-
kinra [15,37], whereas the effect of synthetic DMARDs on DKK-1 production has not been
specifically evaluated.
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This study has strengths and limitations. The strengths are its prospective design, the analy-
sis of the short-term change in the level of the biomarkers (not limited to baseline samples),
and the fact that known confounders in the multivariate analyses are addressed. In addition,
we evaluated for the first time the predictive value of bone remodeling biomarkers in patients
with tightly controlled RA. The main limitations include the relatively small sample size, the
variation in follow-up intervals for patients, and the evaluation of radiological progression per-
formed under different therapeutics. Therefore, we cannot conclusively rule out the possibility
of treatment confounders.
In conclusion, in patients with tightly controlled RA, serum OPG was inversely associated
with the progression of joint destruction.
Contrary to our results and other previous reports [20–25], two recently published studies
question this protective role. Audo et al [38] using data from the ESPOIR cohort showed that a
high OPG/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) was associated
with lack of disease remission in RA and with rapid progression of erosions. In the same line,
Van Steenbergen et al [39] showed that low OPG levels are associated with achieving DAS
remission as well as DMARD-free sustained remission in RA. These discrepancies may be
related by the fact that beside its well-known role in bone metabolism, OPG has pro-inflam-
matory effects that likely act via the activation of the nuclear factor Kappa B pathway [40,41].
Another possible explanation for these divergences could be related by the differences between
the populations studied (our study was performed in patients with tightly controlled RA).
In view of these contradictory results, further studies are required to clarify the relevance of
OPG in disease/progression activity in RA, and to examine whether this biomarker may be use-
ful in combination with other risk factors to improve predictions and guide treatment decisions.
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